- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04423536
Predictive Value of a SNP Signature and Liquid Biopsy in Natural Killer T-cell Lymphoma
May 6, 2022 updated by: Qingqing Cai, Sun Yat-sen University
The purpose of this study is to determine the Predictive value of a SNP signature and liquid biopsy in patients with natural killer T-cell lymphoma.
Study Overview
Status
Recruiting
Conditions
Study Type
Observational
Enrollment (Anticipated)
800
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Guangzhou, China, 51000
- Recruiting
- Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University,
-
Contact:
- Qing qing Cai, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
adults
Description
Inclusion Criteria:
- biopsy proved Natural Killer T-cell Lymphoma
- newly diagnosed patients
Exclusion Criteria:
- patients with biopsy samples unavailable
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
tested group
|
controlled group
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall survival
Time Frame: 5-years
|
5-years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 9, 2021
Primary Completion (Anticipated)
March 1, 2025
Study Completion (Anticipated)
March 1, 2025
Study Registration Dates
First Submitted
June 7, 2020
First Submitted That Met QC Criteria
June 7, 2020
First Posted (Actual)
June 9, 2020
Study Record Updates
Last Update Posted (Actual)
May 9, 2022
Last Update Submitted That Met QC Criteria
May 6, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- B2020-035
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Natural Killer T-cell Lymphoma
-
Won Seog KimSanofiRecruitingNatural Killer/T-cell Lymphoma | Relapsed Natural Killer/T-cell Lymphoma | Refractory Natural Killer/T-cell LymphomaKorea, Republic of
-
Ruijin HospitalNot yet recruiting
-
CStone PharmaceuticalsCompletedExtranodal Natural Killer/T-Cell LymphomaUnited States, China
-
Xinhua Hospital, Shanghai Jiao Tong University...CompletedNatural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeChina
-
Sun Yat-sen UniversityRecruitingExtranodal Natural Killer T Cell LymphomaChina
-
Cancer Institute and Hospital, Chinese Academy...Shanxi Province Cancer Hospital; 307 Hospital of PLA; Qilu Hospital of Shandong... and other collaboratorsUnknownExtranodal Natural Killer/T-Cell Lymphoma, Nasal TypeChina
-
Rong TaoRecruitingNatural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeChina
-
Cancer Institute and Hospital, Chinese Academy...UnknownNatural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeChina
-
Fudan UniversityRecruitingNatural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeChina
-
Rong TaoRecruitingNatural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeChina